Daily PubMed evidence board
FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis pooled five retrospective cohort studies (534 patients) comparing FLAG-based induction regimens with the standard…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42284251Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled five retrospective cohort studies (534 patients) comparing FLAG-based induction regimens with the standard 7+3 regimen in adults newly diagnosed with acute myeloid leukemia (AML). FLAG-based induction was associated with higher odds of overall response (reported pooled OR 1.83, 95% CI 1.03-3.22). There was no statistically significant difference in reported 30-day or 60-day mortality. Survival results were inconsistent across studies and could not be combined reliably; some cohorts showed similar overall survival while others suggested improved survival with FLAG, but these differences appeared linked to what happened after remission (consolidation therapy and transplant). Cytogenetic and molecular risk data were incompletely reported, limiting subgroup conclusions. Authors conclude FLAG improves response rates without clear increases in early mortality, but its effect on long-term survival is uncertain and requires prospective randomized trials.
Why it matters
- Compares FLAG-based induction (fludarabine, cytarabine, G-CSF ± idarubicin/anthracycline) versus the standard cytarabine-daunorubicin (7+3) regimen for frontline therapy in adults with newly diagnosed acute myeloid leukemia (AML).
- Finds higher overall response rate with FLAG-based induction - a key early treatment outcome that can influence remission rates, consolidation decisions, and eligibility for curative allogeneic transplant.
- Reports no clear increase in early (30- or 60-day) mortality, but survival outcomes are heterogeneous and appear dependent on post-remission management, so changes in induction strategy could shift downstream care patterns and resource use.
Primary outcomes
- Overall response rate (OR reported)
- 30-day mortality
- 60-day mortality
- Overall survival (OS)
- Disease-free / relapse-free survival (DFS/RFS)
Effect summary
Abstract-reported quantitative findings: pooled odds ratio for overall response with FLAG-based induction versus 7+3 = 1.83 (95% CI 1.03-3.22). No significant pooled differences for 30-day mortality (OR 0.56, 95% CI 0.12-2.69) or 60-day mortality (OR 0.79, 95% CI 0.29-2.14). Survival outcomes were heterogeneous and not pooled; FLAG associated with higher receipt of consolidation therapy; bridging to allogeneic transplant similar in pooled reports. Cytogenetic/molecular risk reporting was incomplete, preventing reliable subgroup analysis.
Benefit-cost lens
| Quick take | Meta-analysis of retrospective cohorts shows higher odds of overall response with FLAG-based induction (OR 1.83, 95% CI 1.03-3.22) without clear increase in early mortality; survival impact uncertain and likely depends on consolidation and transplant strategies. Benefit-cost conclusions require absolute risks, costs, and implementation assumptions. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Derived from abstract-only meta-analysis of five retrospective cohort studies (n=534). Assumes pooled OR for overall response (1.83) applies to similar populations; full-text verification needed for absolute event rates, heterogeneity sources, toxicity, and subgroup definitions. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Based on abstract of a systematic review/meta-analysis of five retrospective cohort studies. Limitations: retrospective design of included studies, incomplete reporting of cytogenetic/molecular risk and survival outcomes, potential heterogeneity and confounding, and inability to pool survival outcomes. No full RoB tables available from abstract. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review, confirm regimen definitions/dosing, extract absolute event rates and subgroup data, local cost and capacity assessment (drug supply, inpatient supportive care, transplant availability), guideline and domain-expert consultation, and prospective data collection if implemented. |
|---|---|
| Equity impact | Unclear. Equity implications depend on access to FLAG regimen components, supportive care, and transplant capacity; incomplete subgroup reporting limits assessment of differential effects by socioeconomic status, race/ethnicity, or comorbidity. |
| Harms | Abstract does not report pooled harms in detail; early mortality (30- and 60-day) not increased in pooled estimates, but full-text review needed to assess regimen-specific toxicity profiles, hospitalization, infection rates, or longer-term adverse events. |
| Replication | Unknown from automated PubMed triage; replication would require accessing primary cohort data or additional prospective studies. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.